Duke University

Rutgers, the State University of New Jersey

Other

The Research and Development Intstitute

Andrew J Gow

Jonathan S Stamler

Eric John Toone

Gillian M Cannon

Jeffrey D Laskin

Mehdi Javanmard

David J Singel

Manish Chhowalla

Debra L Laskin

Clifford P Weisel

Damien Voiry

Azam Gholizadeh

Robert J Laumbach

Grace L Guo

Howard M Kipen

Jaclynn A Meshanni

A method of treating reduced pulmonary function by administering an effective dose of a Farnesoid X Receptor (FXR) agonist, particularly obeticholic acid, is disclosed. Also disclosed is an in vivo animal model of lung injury and altered functioning, useful for identifying compounds active in restoring pulmonary function.

Pulmonary function treatment

A cardiovascular health assessment score, representing a working tissue flow and indicating the dependence on central and peripheral control mechanisms, is generated by an evaluation system and used to support a variety of individualized medicine and health applications. One or more of the individualized medicine and health applications may be implemented as part of the evaluation system and incorporate the cardiovascular health assessment.

Evaluation system for cardiovascular health assessment and individualized health and fitness interventions

A cardiovascular health assessment score, representing a working tissue flow and indicating the dependence on central and peripheral control mechanisms, is generated by the evaluation system and used to support a variety of individualized medicine and health applications. One or more of the individualized medicine and health applications may be implemented as part of the evaluation system and incorporate the cardiovascular health assessment.

A device for detecting a biomarker for inflammation in a respiratory system includes a sample collection and/or holding area to receive an exhaled breath condensate (EBC) sample obtained from a respiratory system; an electrode system coupled to the sample collection area, the electrode system including reduced graphene oxide (rGO); and circuitry coupled to the electrode system. The circuitry is configured to apply a voltage to the EBC sample in the sample collection area via the electrode system and to measure a current via the electrode system in response to the voltage applied, in order to determine a concentration of nitrite in the EBC sample based on the current measured. The concentration of nitrite is a biomarker for inflammation in the respiratory system.

Quantification of inflammatory molecules in exhaled breath condensate using differential pulse voltammetry on reduced graphene oxide sensor

The present invention relates to methods of treatment of pulmonary disorders associated with hypoxemia and/or smooth muscle constriction and/or inflammation; treatment of cardiac and blood disorders; treatment of patient in need of improved oxygenation, blood flow of and/or thinning of blood and method of screening drugs that increase level of nitrosoglutathione in airway lining fluid.

Methods for treating cardio pulmonary diseases with NO group compounds

Nitrosylhemoglobin can be produced by introducing gaseous NO into an aqueous solution of hemoglobin. It has been demonstrated that nitrosylhemoglobin in aqueous solution can be converted to SNO-hemoglobin upon introduction of oxygen to the solution, as is postulated to occur in the lungs. Nitrosylhemoglobin can be used in methods to produce the physiological effects of NO, for example, to reduce vasoconstriction and to inhibit platelet aggregation.

No-modified hemoglobins and uses therefor

Treatment of pulmonary disorders associated with hypoxemia and/or smooth muscle constriction and/or inflammation comprises administering into the lungs as a gas compound with an NO group which does not form NO/NOin the presence of oxygen or reactive oxygen species at body temperature. Treatment of cardiac and blood disorders, e.g., angina, myocardial infarction, heart failure, hypertension, sickle cell disease and clotting disorders, comprises administering into the lungs as a gas, a compound which reacts with cysteine in hemoglobin and/or dissolves in blood and has an NO group which is bound in said compound so that it does not form NO/NOin the presence of oxygen or reactive oxygen species at body temperature. Exemplary of the compound administered in each case is ethyl nitrite.

Method of treating cardio pulmonary diseases with no group compounds

Diseases which can be ameliorated by delivery of NO to tissues affected by the disease can be treated by administration of nitrosyl-heme-containing donors of NO, including nitrosylhemoglobin. Nitrosylhemoglobin can be made by the reaction of NO with hemoglobin under certain conditions in which the NO:hemoglobin ratio is critical, and is converted to SNO-Hb under physiological conditions.

Modified hemoglobins, including nitrosylhemoglobins, and uses thereof

Treatment of pulmonary disorders associated with hypoxemia and/or smooth muscle constriction comprises administering into the lungs as a gas a compound with an NO group which does not form NO,/NO,in the presence of oxygen or reactive oxygen species at body temperature. Treatment of cardiac and blood disorders, e.g., angina, myocardial infarction, heart failure, hypertension, sickle cell disease and clotting disorders, comprises administering into the lungs as a gas, a compound which reacts with cysteine in hemoglobin and/or dissolves in blood and has an NO group which is bound in said compound so that it does not form NO,/NO,in the presence of oxygen or reactive oxygen species at body temperature. Exemplary of the compound administered in each case is ethyl nitrite.

Growing community of inventors

Princeton, NJ, United States of America

Andrew J Gow